Eli Lilly and Company
Eli Lilly and Company develops and markets pharmaceuticals worldwide for various conditions, including diabetes, type 2 diabetes, obesity, oncology products, rheumatoid arthritis, psoriasis, ulcerative colitis, depression, anxiety disorders, fibromyalgia, osteoporosis, and more. Its products include Basaglar, Humalog, Jardiance, Mounjaro, Trulicity, Zepbound, and others. The company also collaborates with other organizations. Founded in 1876, Lilly is headquartered in Indiana.
Overview
Strengths
- Return on invested capital has stayed above 15% in 5 of the last 6 years (latest 24.4%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 24.4% against a cost of capital (WACC) of 6.5%, a spread of 17.9 percentage points.
- Consistent growth: revenue has compounded at 21.6% a year over 5 years, rising every year.
- Scale advantage: ranks #1 by enterprise value ($1.3 trillion) among the 28 Drug Manufacturers - General companies we cover.
- Shareholder-friendly capital allocation: the share count has shrunk by 2.0% a year over the last three years through buybacks.
- EBITDA margin of 53.8% beats 100% of its 27 Drug Manufacturers - General peers (median 34.4%).
Weaknesses
- Our discounted cash flow target price (300.67 USD) is 78% below the current price.
- Valued at a premium to its Drug Manufacturers - General peers: P/E 59.2x vs. a median of 22.1x and EV/EBITDA 35.8x vs. a median of 13.7x.
Key Financial Data